Valeant To Acquire Bausch & Lomb For $8.7 Billion

Valeant To Acquire Bausch & Lomb For $8.7 Billion

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) in one of its biggest and important deals, announced Monday of it plans to acquire Bausch & Lomb for $8.7 billion.

valeant logo

The acquisition of the privately held ophthalmology business marks the biggest of the 60 takeovers made by Michael Pearson since he took over the leadership at Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) five years ago. This strategy followed by Pearson of acquisitions fuelled by debt has helped in enhancing the groups share price.

Bonhoeffer Fund July 2022 Performance Update

Screenshot 27Bonhoeffer Fund's performance update for the month ended July 31, 2022. Q2 2022 hedge fund letters, conferences and more The Bonhoeffer Fund returned 3.5% net of fees in July, for a year-to-date return of -15.8%.   Bonhoeffer Fund, LP, is a value-oriented private investment partnership for . . . SORRY! This content is exclusively for Read More

The deal will help in the annual savings of $800 million by 2014 and will start generating cash from the very first year.

Valeant terms of the deal

As per the deal, speciality pharmaceuticals group Val